Recombinant human mannose-binding lectin(NatImmune A/S)(Recombinant human mannose-binding lectin(NatImmune A/S))

概要

基本信息

药物类型

重组蛋白

别名

Recombinant human mannan-binding protein、Recombinant human mannose-binding lectin、rhMBL

+ [1]

靶点

LMAN1

作用机制

LMAN1刺激剂(lectin, mannose binding 1 stimulants)、补体激活刺激剂

治疗领域

感染肿瘤免疫系统疾病+ [5]

在研适应症-

非在研适应症

发热潮热感染+ [7]

原研机构

Azanta Danmark A/S

在研机构-

非在研机构

Enzon Pharmaceuticals, Inc.Azanta Danmark A/S

最高研发阶段终止临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

序列信息

Sequence Code 611653161

关联

3

项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的临床试验

NCT00415311 / Terminated临床1期

A Multicenter, Open-Label, Randomized, Phase 1B Study Evaluating the Safety and Tolerability of Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL) in Liver Transplant Recipients

This is a multicenter, open-label, randomized, Phase 1B study evaluating liver transplant recipients receiving rhMBL (2 cohorts) or without rhMBL (1 cohort).

开始日期2006-12-01

申办/合作机构

Enzon Pharmaceuticals, Inc.

NCT00886496 / Withdrawn临床1期

A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients With Fever and Neutropenia

RATIONALE: Recombinant human mannose-binding lectin (MBL) may be effective in preventing infection in young patients with fever and neutropenia receiving chemotherapy for blood disease or cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of recombinant human mannose-binding lectin in treating young patients with MBL deficiency and fever and neutropenia.

开始日期2006-11-01

申办/合作机构

Enzon Pharmaceuticals, Inc.

[+1]

NCT00388999 / Completed临床1期

Multi-Center,Open-Label,Randomized,Phase 1B Study Evaluating Safety & Tolerability of Intravenous rhMBL in Pts With Multiple Myeloma Receiving Melphalan-Based High-Dose Chemotherapy Followed by Autologous Hematopoietic Stem Cell Transplant

MBL deficient patients enrolled in this protocol are scheduled to be treated with melphalan-based high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) for their multiple myeloma. Patients are randomized to 0.5 mg/kg, 1.0 mg/kg, or no rhMBL.

开始日期2006-09-01

申办/合作机构

Enzon Pharmaceuticals, Inc.

100 项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的专利（医药）

登录后查看更多信息

24

项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的文献（医药）

2022-04-01·Methods and Applications in Fluorescence3区 · 化学

Mannose-binding lectin conjugated to quantum dots as fluorescent nanotools for carbohydrate tracing

3区 · 化学

Article

作者: Lima, Carinna N ; Juul-Madsen, Kristian ; Oliveira, Weslley F ; Moura, Patrícia ; Silva, Paloma M M ; Vorup-Jensen, Thomas ; Fontes, Adriana ; Filho, Paulo E Cabral

AbstractQuantum dots (QDs) have stood out as nanotools for glycobiology due to their photostability and ability to be combined with lectins. Mannose-binding lectin (MBL) is involved in the innate immune system and plays important roles in the activation of the complement cascade, opsonization, and elimination of apoptotic and microbial cells. Herein, adsorption and covalent coupling strategies were evaluated to conjugate QDs to a recombinant human MBL (rhMBL). The most efficient nanoprobe was selected by evaluating the conjugate ability to label Candida albicans yeasts by flow cytometry. The QDs-rhMBL conjugate obtained by adsorption at pH 6.0 was the most efficient, labeling ca. 100% of cells with the highest median fluorescence intensity. The conjugation was also supported by Fourier transform infrared spectroscopy, zeta potential, and size analyses. C. albicans labeling was calcium-dependent; 12% and <1% of cells were labeled in buffers without calcium and containing EDTA, respectively. The conjugate promoted specific labeling (based on cluster effect) since, after inhibition with mannan, there was a reduction of 80% in cell labeling, which did not occur with methyl-α-D-mannopyranoside monosaccharide. Conjugates maintained colloidal stability, bright fluorescence, and biological activity for at least 8 months. Therefore, QDs-rhMBL conjugates are promising nanotools to elucidate the roles of MBL in biological processes.

2020-08-01·Journal of Cerebral Blood Flow & Metabolism2区 · 医学

Mannose-binding lectin has a direct deleterious effect on ischemic brain microvascular endothelial cells

2区 · 医学

Article

作者: De Simoni, Maria-Grazia ; Zanetti, Adriana ; Perego, Carlo ; Orsini, Franca ; Neglia, Laura ; Fumagalli, Stefano

Mannose-binding lectin (MBL), an initiator of the lectin pathway, is detrimental in ischemic stroke. MBL deposition on the ischemic endothelium indicates the beginning of its actions, but downstream mechanisms are not clear yet. We investigated MBL interactions with the ischemic endothelium by exposing human brain microvascular endothelial cells (hBMECs) to protocols of ischemia. Cells were exposed to hypoxia or oxygen–glucose deprivation (OGD), and re-oxygenated with human serum (HS) or recombinant MBL (rhMBL). Hypoxic hBMECs re-oxygenated with HS showed increased complement system activation (C3c deposition, +59%) and MBL deposition (+93%) than normoxic cells. Super-resolution microscopy showed MBL internalization in hypoxic cells and altered cytoskeletal organization, indicating a potential MBL action on the endothelial structure. To isolate MBL effect, hBMECs were re-oxygenated with rhMBL after hypoxia/OGD. In both conditions, MBL reduced viability (hypoxia: −25%, OGD: −34%) compared to conditions without MBL, showing a direct toxic effect. Ischemic cells also showed greater MBL deposition (hypoxia: +143%, OGD: +126%) than normoxic cells. These results were confirmed with primary hBMECs exposed to OGD (increased MBL-induced cell death: +226%, and MBL deposition: +104%). The present findings demonstrate that MBL can exert a direct deleterious effect on ischemic brain endothelial cells in vitro, independently from complement activation.

2019-02-22·ACS Sensors

Label-Free Potentiometric Ion Flux Immunosensor for Determination of Recombinant Human Myelin Basic Protein: Application to Downstream Purification from Transgenic Milk

Article

作者: Nebsen, Marianne ; Nadim, Ahmed H. ; Al-Ghobashy, Medhat A. ; El-Sayed, Ghada M.

Recombinant human myelin basic protein (rhMBP) produced in the milk of transgenic cows was found exclusively associated with milk caseins. This hindered its direct determination without extensive sample pretreatment. Here, a label-free potentiometric immunosensor was developed and validated for the determination of rhMBP. An ion flux was generated under zero-current based on surface blocking of the polymeric membrane ion-selective electrode by anti-hMBP antibody and tetrabutylammonium bromide as a marker ion. The immunosensor was successfully employed in the quantitative determination of hMBP in the range of 0.10-20.00 μg/mL with a limit of detection of 50.00 ng/mL. The applicability of the passive ion flux immunosensor for determination of target analyte in complex matrices was investigated. Downstream purification of rhMBP from the milk of transgenic cows was achieved using cation exchange chromatography, immobilized metal affinity chromatography, and immunoaffinity chromatography. The specificity of the immunosensor along with matrix effect of milk proteins were demonstrated. Results obtained using the rhMBP immunosensor were further cross-validated using an orthogonal testing protocol assembled of RP-HPLC and SE-HPLC. It should be noted that the proposed ion flux immunosensor provided a feasible and specific tool for monitoring rhMBP concentration/purity, immunogenic activity, and stability. Such approach provides an attractive economic alternative to sophisticated biosensors required for in-process quality control of biopharmaceutical products.

100 项与 Recombinant human mannose-binding lectin(NatImmune A/S) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05237

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
发热	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
潮热	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
白血病	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
甘露糖结合蛋白缺乏症	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
骨髓增生异常综合征	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
中性粒细胞减少	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
实体瘤	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-11-01
多发性骨髓瘤	临床2期	美国	Enzon Pharmaceuticals, Inc.	2006-09-01
感染	临床2期	-	Azanta Danmark A/S	-
感染	临床2期	美国	Enzon Pharmaceuticals, Inc.	-